Mylan, Biocon in deal on insulin products

Mylan and Biocon Ltd. are in a partnership to develop and commercialize three generic insulin analog products. Financial terms of the profit-sharing deal weren't disclosed. But Mylan will be able to develop Glargine, the generic version of Sanofi's Lantus; Lispro, the generic version of Eli Lilly's Humalog; and Aspart, the generic version of Nov Nordisk's NovoLog. The rights are for the U.S., Canada, the European Union and elsewhere. The worldwide sales of the three are $11.5 billion in 2012, Mylan…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Source Type: research